Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on Crinetics (CRNX) to $88 from $89 and keeps an Outperform rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics price target lowered to $84 from $87 at Oppenheimer
- Crinetics Pharma Earnings Call Highlights Palsonify Momentum
- Crinetics price target lowered to $95 from $97 at Citizens
- Crinetics reports Q1 EPS ($1.23), consensus ($1.24)
- Analyst Maintains Buy on Palsonify Amid Strong Global Growth Prospects Despite Trimmed Price Target to $90